Healthcare
Live Price
Offline$40.10
+2.48% today
1Y Change
-10.57%
Window
Jun 23, 2025 → Jun 10, 2026
Coverage: 243 bars · Jun 23, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vericel Corporation (VCEL) is a Healthcare stock with a market cap of $1.81B and listed on NASDAQ. The stock last traded around $40.10 and down 10.6% across the available one-year price window (Jun 23, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of +16.5%, EPS growth of +57.1%, a dividend yield of 0.0%. What stands out right now is revenue +16.5%, EPS +57.1%, free cash flow +525.9% with operating margin 4.0% and ROIC 2.3%. Valuation already assumes a fairly strong business story at P/E 108.9 and price/sales 6.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VCEL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VCEL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VCEL Max Drawdown
-32.30%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VCEL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$156.2M
-5.0% YoY
FY Net Income
-$7.5M
+55.3% YoY
Free Cash Flow
$21.1M
+109.3% YoY
Revenue Growth
+16.5%
EPS Growth
+57.1%
Gross Margin
74.4%
Net Margin
6.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 276M | 237M | 198M | 164M | 156M |
| Gross Profit | 206M | 172M | 136M | 110M | 106M |
| Operating Income | 11M | 5M | -6M | -17M | -8M |
| EBITDA | 30M | 17M | 3M | -12M | -5M |
| Net Income | 17M | 10M | -3M | -17M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 100M | 75M | 69M | 51M | 68M |
| Total Assets | 488M | 433M | 354M | 273M | 244M |
| Total Liabilities | 133M | 141M | 128M | 81M | 73M |
| Shareholder Equity | 355M | 292M | 226M | 192M | 170M |
| Total Debt | 98M | 99M | 88M | 48M | 50M |
| Net Debt | -2M | 24M | 19M | -3M | -18M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
29M
+64.2% YoY
Capital Expenditures
8M
-4.2% YoY
Free Cash Flow
21M
+109.3% YoY
Key ratios
Gross Margin
74.4%
Operating Margin
4.0%
Net Margin
6.0%
ROE
5.2%
Debt / Equity
0.28x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.